We are live on
!
Find out more
GPP
Great Point Partners Portfolio holdings
AUM
$435M
1-Year Est. Return
318.81%
This Fund
S&P 500
This Quarter
Est. Return
+21.39%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$308M
AUM Growth
+$65.9M
(+27%)
Cap. Flow
+$53.9M
Cap. Flow
% of AUM
17.47%
Top 10 Holdings %
Top 10 Hldgs %
62.02%
Holding
42
New
12
Increased
6
Reduced
4
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vor Biopharma
VOR
|
+$25.5M |
| 2 |
Disc Medicine
IRON
|
+$21.1M |
| 3 |
RAPT
RAPT Therapeutics
RAPT
|
+$18M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$9.87M |
| 5 |
SLNO
Soleno Therapeutics
SLNO
|
+$9.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ascendis Pharma A/S
ASND
|
+$14.9M |
| 2 |
ABVX
Abivax
ABVX
|
+$12.7M |
| 3 |
Rezolute
RZLT
|
+$11.8M |
| 4 |
Cytokinetics
CYTK
|
+$8.24M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$8.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sana Biotechnology
SANA
$885M
| $2.85M | 0.92% |
700,000
| – | – |
|
27
Pharvaris
PHVS
$2.39B
| $2.3M | 0.75% |
82,800
-72,305
| -47% | -$1.74M |
|
28
Avalo Therapeutics
AVTX
$976M
| $2.26M | 0.73% |
+124,666
| New | +$2.1M |
|
|
29
Rezolute
RZLT
$480M
| $2.25M | 0.73% |
951,809
-1,500,000
| -61% | -$11.8M |
|
30
Absci
ABSI
$1.28B
| – | – |
-796,438
| Closed | -$2.42M |
|
|
ABVX
31
Abivax
ABVX
$11B
| – | – |
-150,000
| Closed | -$12.7M |
|
|
AKRO
32
DELISTED
Akero Therapeutics
AKRO
| – | – |
-103,848
| Closed | -$4.93M |
|
|
33
Ascendis Pharma A/S
ASND
$16.7B
| – | – |
-75,000
| Closed | -$14.9M |
|
34
PUT
Capricor Therapeutics
CAPR
$1.14B
| – | – |
-87,700
| Closed | -$632K |
|
|
35
Cytokinetics
CYTK
$11B
| – | – |
-150,000
| Closed | -$8.24M |
|
|
DBVT
36
DBV Technologies
DBVT
$807M
| – | – |
-378,594
| Closed | -$3.79M |
|
37
CALL
Harmony Biosciences
HRMY
$2.04B
| – | – |
-85,000
| Closed | -$2.34M |
|
38
Ionis Pharmaceuticals
IONS
$9.35B
| – | – |
-80,000
| Closed | -$5.23M |
|
39
Legend Biotech
LEGN
$4.3B
| – | – |
-113,460
| Closed | -$3.7M |
|
40
Pliant Therapeutics
PLRX
$67.5M
| – | – |
-850,000
| Closed | -$1.26M |
|
41
Taysha Gene Therapies
TSHA
$1.59B
| – | – |
-1,500,000
| Closed | -$4.91M |
|
|
42
Xenon Pharmaceuticals
XENE
$6.32B
| – | – |
-200,000
| Closed | -$8.03M |
|
Similar funds
GDS
JWM
SWG
SCP
NF
VIM
VDBMI
ACG
Great Point Partners's Q4 2025 Portfolio in Review
As of Q4 2025, Great Point Partners held 42 positions worth $308M, up 27% from $242M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Great Point Partners deployed $53.9M of net new capital in Q4 2025, opening 12 new positions and adding to 6 existing holdings. Its largest new stake was Vor Biopharma: 1,370,107 shares worth $17.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.
On the sell side, the largest reduction was Rezolute, an estimated $11.8M trimmed.
- Great Point Partners's largest Q4 2025 buy was Vor Biopharma: 1,370,107 shares worth $17.9M.
- Great Point Partners added most to Soleno Therapeutics in Q4 2025, an estimated $9.6M increase.
- Great Point Partners's biggest Q4 2025 reduction was Rezolute, cutting an estimated $11.8M.
- Great Point Partners fully exited Ascendis Pharma A/S in Q4 2025, selling an estimated $14.9M.
- Great Point Partners's ten largest holdings make up 62% of its $308M portfolio in Q4 2025.
- Great Point Partners opened 12 new positions and closed 13 in Q4 2025.
- Great Point Partners's portfolio value rose 27% quarter-over-quarter to $308M.
Based on Great Point Partners's 13F filing for Q4 2025, filed 17 Feb 2026.